Wall Street brokerages predict that Trevena Inc (NASDAQ:TRVN) will report earnings of ($0.20) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Trevena’s earnings. The highest EPS estimate is ($0.18) and the lowest is ($0.22). Trevena reported earnings of ($0.36) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 44.4%. The business is scheduled to report its next quarterly earnings report on Thursday, May 3rd.
According to Zacks, analysts expect that Trevena will report full year earnings of ($0.96) per share for the current financial year, with EPS estimates ranging from ($1.17) to ($0.82). For the next financial year, analysts expect that the firm will post earnings of ($0.76) per share, with EPS estimates ranging from ($1.22) to ($0.41). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side research firms that follow Trevena.
Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.02.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Nationwide Fund Advisors raised its stake in shares of Trevena by 92.1% in the second quarter. Nationwide Fund Advisors now owns 49,132 shares of the biopharmaceutical company’s stock worth $113,000 after acquiring an additional 23,557 shares during the last quarter. Alliancebernstein L.P. raised its stake in shares of Trevena by 51.9% in the second quarter. Alliancebernstein L.P. now owns 55,300 shares of the biopharmaceutical company’s stock worth $127,000 after acquiring an additional 18,900 shares during the last quarter. Millennium Management LLC bought a new position in shares of Trevena in the fourth quarter worth about $130,000. American Century Companies Inc. bought a new position in shares of Trevena in the fourth quarter worth about $135,000. Finally, California State Teachers Retirement System raised its stake in shares of Trevena by 0.5% in the second quarter. California State Teachers Retirement System now owns 97,107 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 500 shares during the last quarter. 52.50% of the stock is owned by institutional investors.
Trevena (NASDAQ TRVN) opened at $1.92 on Tuesday. Trevena has a 1-year low of $1.34 and a 1-year high of $3.98. The stock has a market cap of $119.62, a PE ratio of -1.57 and a beta of -0.61. The company has a current ratio of 3.71, a quick ratio of 3.71 and a debt-to-equity ratio of 0.45.
WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/03/13/trevena-inc-trvn-expected-to-announce-earnings-of-0-20-per-share.html.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.